AXAxinet
Menu
Finance

Live market screen

Commercial Space Company Risk / Opportunity Ranking

Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.

Updated June 27, 2026

Companies analyzed
438
Ranked rows
876
Evidence links
356
Rows per page
20

Opportunity view

Showing rows 401-420 of 438; 20 rows per page.

Sorted by raw opportunity score
RankCompanyScoreThesis / Evidence
401
Vantor
lowweak
Opp 1
Risk 1

Thesis: Vantor's membership rationale suggests spatial-intelligence and constellation expansion relevance, but there are no retained evidence or article summaries within the recent evidence window to support a current opportunity thesis.

Why now: Why now is weak because the reviewed sources contain no retained post-cutoff directional evidence.

Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without and cannot be cited directly here.

402
Varda Space Industries
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources confirms cohort relevance, but it contains no retained 90-day direct positive evidence to support a durable 1 year+ upside thesis.

Why now: No within the recent evidence window company-specific evidence were available after filtering; articles after recent evidence window and evidence after recent evidence window are both zero in coverage data, so recency-based thesis formation is not supported in these reviewed sources.

Caveats: 12 articles were considered historically, but zero article IDs remained after the 90-day recent evidence filter. Membership rationale cites older support article IDs but those underlying evidence are not retained in the served reviewed sources. Scores are constrained by evidence absence, not by a documented negative business development.

403
Venturi Astrolab
lowweak
Opp 1
Risk 1

Thesis: The phase-2 rationale references NASA moon buggy contracts and moon base planning tied to articles: and: which could have supported an opportunity case, but these reviewed sources provide no representative article details, or retained evidence after recent evidence window. Therefore no grounded positive thesis can be advanced here.

Why now: Why now is weak because despite 30 articles considered, coverage data shows articles after recent evidence window of 0 and evidence recent evidence review kept_rows of 0, so the reviewed sources does not preserve dated supporting evidence inside the 90-day window.

Caveats: Phase-2 rationale cannot substitute for cited article evidence because are absent. No direct positive or negative evidence arrays are populated. Low scores are driven by evidence retention limits in these reviewed sources.

404
Virgin Galactic Holdings, Inc.
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources does not provide direct positive evidence inside the scoring fields, so no positive investment thesis is supportable here.

Why now: The phase2 rationale references three article IDs, but the reviewed sources includes no representative article summaries or evidence to cite for a dated catalyst. Coverage data shows zero article IDs after recent evidence window and zero available evidence, so the current-state thesis is unsupported by reviewed sources detail.

Caveats: Do not infer direction from company identity or sector relevance alone. Phase2 membership support cannot substitute for direct thesis evidence.

405
Vyoma GmbH
lowweak
Opp 1
Risk 1

Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, even though membership rationale says Vyoma is an SDA company selected by ESA and flying SSA sensors.

Why now: Why now is unsupported because the reviewed sources contain no surviving evidence after recent evidence filtering; timing and business-state changes cannot be validated from the provided material.

Caveats: Zero evidence after recent evidence filtering. Membership rationale alone is not sufficient for directional scoring. No direct dated catalyst or adverse development is provided.

406
Windward Ltd.
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources provide no direct positive company-specific evidence after recent evidence window. The only described context is that Vantor partnered with Windward for maritime awareness, but relations are context-only unless separately gated and cannot be used as counterparty propagation evidence.

Why now: No catalyst is established. Coverage debug shows 27 article IDs considered but 0 after recent evidence window and 0 evidence available.

Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Relation context is explicitly weaker and not valid counterparty propagation evidence.

407
WISeKey International Holding Ltd
lowweak
Opp 1
Risk 1

Thesis: The reviewed sources indicates space-related operations through WISeSat, but provides no retained within the recent evidence window direct positive evidence or article to support an opportunity thesis.

Why now: There are zero available evidence after recent evidence window for ranking, so no evidence-backed timing signal is available.

Caveats: Membership support mentions 21 LEO satellites launched and operational space-related infrastructure, but those claims are not accompanied here by retained ranking evidence or article. Without dated evidence inside the recent evidence window, score should remain low-conviction.

408
York Space Systems
lowweak
Opp 1
Risk 1

Thesis: The membership rationale references public listing status and defense contract momentum, but no retained within the recent evidence window direct evidence or article summaries are available here to support a positive thesis.

Why now: The reviewed sources have no retained dated evidence after the 90-day recent evidence window, so there is no citable timing edge for a 1 year+ ranking.

Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs and, but no or retained evidence text are provided here. Later-dated evidence could supersede older listing or contract-status claims, but no such retained evidence exists in these reviewed sources.

409
York Space Systems
lowweak
Opp 1
Risk 1

Thesis: The membership rationale suggests meaningful satellite-manufacturing and tactical-communications activity, but the reviewed sources retains no direct evidence within the recent evidence window to support a positive thesis.

Why now: Although membership support cites articles, and: no representative summaries or retained evidence are included here, leaving no current catalyst basis.

Caveats: 54 articles considered, but 0 retained after recent evidence filtering. Cannot elevate based on membership rationale alone.

410
Akashalabdhi
lowweak
Opp 0
Risk 0

Thesis: No positive thesis is supportable because the reviewed sources contain no direct positive evidence for Akashalabdhi within the recent evidence window.

Why now: There is no visible near-term or long-horizon company-specific catalyst in the reviewed sources. The membership review explicitly says the only included article does not mention Akashalabdhi in the visible summary, and coverage debug shows zero articles and zero evidence after recent evidence window.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article. Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. The reviewed sources itself says visible evidence is insufficient to determine even qualifying membership.

411
Amentum Holdings Inc.
lowweak
Opp 0
Risk 0

Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite large historical mention volume.

Caveats: Phase-2 rationale references article IDs and, but no article summaries or retained evidence are included here. Historical aerospace exposure does not create a current directional thesis without retained evidence.

412
Apparition Geoservices GmbH
lowweak
Opp 0
Risk 0

Thesis: No positive thesis can be established because no direct positive evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering.

Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership.

413
Arkeon
lowweak
Opp 0
Risk 0

Thesis: No positive thesis is supported because Arkeon has no direct positive evidence in the reviewed sources within the selected recent evidence window.

Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence.

414
Ars Magna Semiconductors
lowweak
Opp 0
Risk 0

Thesis: No positive thesis can be formed because the reviewed sources includes no direct positive evidence for Ars Magna Semiconductors within the recent evidence window.

Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof.

415
Augusta Labs
lowweak
Opp 0
Risk 0

Thesis: No positive thesis is supportable because the reviewed sources have no direct positive evidence for Augusta Labs after recent evidence filtering.

Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available.

416
BeatpulseLabs
lowweak
Opp 0
Risk 0

Thesis: No positive thesis can be justified because no direct positive evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window.

Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof.

417
Bluestaq
lowweak
Opp 0
Risk 1

Thesis: No positive thesis is supported. The reviewed sources say Bluestaq is mentioned only through an executive's prior role at the company, which is indirect context rather than company-specific business evidence (: unavailable in reviewed sources).

Why now: There is no clear why-now catalyst because the only reference is an indirect executive-background mention, with no direct event, product, contract, or financing evidence available.

Caveats: No current evidence is provided for Indirect mention via an executive's prior role is not direct company evidence. Zero evidence available after recent evidence window.

418
Bose Corporation
lowweak
Opp 0
Risk 0

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Bose Corporation after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

419
Breaking Change
lowweak
Opp 0
Risk 0

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Breaking Change after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

420
CameraMatics
lowweak
Opp 0
Risk 0

Thesis: No positive thesis can be supported because there is no direct positive evidence for CameraMatics in the reviewed sources after recent evidence filtering.

Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available.

Risk view

Showing rows 101-120 of 438; 20 rows per page.

Sorted by raw risk score
RankCompanyScoreThesis / Evidence
101
Portal Space Systems
lowweak
Opp 4
Risk 3

Thesis: Debris-removal and spacecraft execution risk are plausible, but the reviewed sources includes no direct negative evidence and no usable article summaries to confirm timing or traction.

Why now: Potential why-now would be the reported Series A and service positioning, but recency cannot be verified because no evidence are retained after the recent evidence window.

Caveats: Phase2 membership rationale references: but no article summary or evidence are included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Slightly higher opportunity than some peers only because the reviewed sources rationale mentions both financing and product/service positioning.

102
RapidTek
lowweak
Opp 5
Risk 3

Thesis: No direct adverse evidence is present. Main risk is scaling from connectivity demonstration to operational network and customer adoption, especially since the reviewed sources contain only one supporting article and no revenue or contract evidence.

Why now: Why now is the reported successful satellite-ground connection and stated LEO IoT ambition referenced in article ID, though the reviewed sources does not include the article or exact timing details.

Caveats: The technical milestone is described only in membership rationale, not available direct evidence. Article ID has no in the reviewed sources. Technical connectivity milestone is weaker than contracted commercial deployment.

103
Reaction Dynamics
lowweak
Opp 3
Risk 3

Thesis: Rocket startup execution risk remains material because the reviewed sources provide no kept direct evidence on funding amount, milestone completion, engine or launch readiness, customer backlog, or follow-on capital.

Why now: The support is tied to article: in the membership rationale, which suggests a relatively recent funding-related development, but the active evidence set still contains zero available rows after recent evidence filtering.

Caveats: Government funding mention is promising but unquantified in the active evidence set. No chronology-confirmed operational updates are available.

104
Redwire Corporation
mediummedium
Opp 6
Risk 3

Thesis: Risk is moderate because the available evidence is still supporting article context rather than direct dated event/facts, and one duplicate/related article is undated, which weakens recency certainty. There is no available material adverse evidence, but execution and commercialization assumptions are not independently corroborated by stronger reviewed sources rows.

Why now: The why-now case is the best in the set: a published June 4, 2026 article says Redwire was awarded a contract from Astrobiome Space for the inaugural flight of its commercial space greenhouse on the ISS. Earlier, on April 8, 2026, Defense Daily reported Redwire among companies awarded more than $1.8 billion total under the Andromeda SDA contracts. Those dated items suggest current business momentum that could matter over a 1 year+ horizon.

Evidence
  • Published June 4, 2026: Redwire announced it was awarded a contract from Astrobiome Space to grow strawberries and test a soil enhancement product inside Redwire’s Greenhouse systems on the ISS; the article says this marks the inaugural flight for Redwire’s commercial space greenhouse. stocktitan.net
  • Published April 8, 2026: Defense Daily says the U.S. Space Force awarded 14 companies more than $1.8 billion in Andromeda contracts and lists Redwire among the companies. defensedaily.com

Caveats: Evidence is weak-context/supporting article context, not direct positive events. The standard-journal article carrying similar June 4, 2026 text is undated in the reviewed sources and should not be treated as independent confirmation. No material adverse evidence is available, but absence of negative evidence is not proof of low risk.

105
Sidus Space Inc.
lowweak
Opp 2
Risk 3

Thesis: Risk is slightly elevated versus some peers because the company has a larger article universe but zero retained evidence in these reviewed sources, leaving a material information gap. Without direct within the recent evidence window evidence, current contract health, financing, or execution cannot be judged.

Why now: Why now is weak because although the company had 44 considered articles, the reviewed sources show articles after recent evidence window = 0 and evidence after recent evidence window = 0, so the current business state is not evidenced here.

Caveats: Phase-2 membership rationale references: and: but no or available evidence are provided. A large historical article universe should not be mistaken for conviction. No within the recent evidence window direct evidence is available for ranking.

106
Sierra Nevada Corporation
lowweak
Opp 3
Risk 3

Thesis: Risk is also elevated relative to peers because the reviewed sources say stronger contract evidence concerns Sierra Space rather than Sierra Nevada Corporation, and the evidence mix may blur entity boundaries, making any thesis vulnerable to misattribution.

Why now: If the referenced constellation and on-orbit transmission activity are current, they could matter over a 1 year+ horizon; however, the reviewed sources provide no available after-recent evidence window evidence to confirm recency or milestone sequence.

Caveats: Phase-2 rationale references: and: but no or article summaries are included. The reviewed sources explicitly warns that the evidence mixes SNC and Sierra Space-adjacent themes. Coverage debug shows zero evidence after recent evidence window, so direct validation is unavailable.

107
Skylo Technologies
lowweak
Opp 2
Risk 3

Thesis: Main risk is evidence scarcity rather than reviewed sources-proven business deterioration. With zero reviewed evidence after the 90-day recent evidence window, there is limited support for either commercial progress or downside.

Why now: There is no fresh kept article evidence after the March 29, 2026 cutoff; timing support is weak and recency is effectively absent in the ranking payload.

Caveats: No evidence were kept after recent evidence window for ranking. Membership rationale is not sufficient by itself for a strong directional thesis.

108
Spacecoin
lowweak
Opp 3
Risk 3

Thesis: Risk is equally meaningful because the described model appears highly conceptual in the reviewed sources, and the evidence does not clearly establish operational satellite-communications scale, contract traction, or validated commercial milestones.

Why now: If the network concept is advancing, that could be relevant over a long horizon, but the reviewed sources offers no available recency-validated milestone evidence after recent evidence window.

Caveats: Phase-2 rationale references and, but no or summaries are included. Business-model adjacency to satellite communications is not the same as proven operating traction. Coverage debug shows zero evidence after recent evidence window.

109
Starfish Space
mediumstrong
Opp 7
Risk 3

Thesis: Starfish remains execution-sensitive because the thesis depends on converting funding and government-backed validation into mission delivery and scaled production, but the reviewed sources does not contain direct adverse events.

Why now: The timing is favorable for a 1 year+ horizon because recent financing on April 7, 2026 was explicitly tied to executing first servicing missions and boosting production, following prior government contract momentum

Evidence
  • Published April 7, 2026: Starfish Space raised more than $100 million in a Series B to scale production of its satellite servicing spacecraft. spacenews.com
  • Published April 7, 2026: The roughly $110 million round would help execute first satellite servicing missions and scale operations. geekwire.com
  • Company-linked extracted fact says Starfish raised over $100 million for satellite servicing and has contracts with Space Force, NASA, and SES. spacenews.com

Caveats: The strongest support is external web-search evidence, though it is company-linked and dated. Some contract details in weaker article context vary and should not be over-aggregated across repeated articles.

110
Synspective
mediummedium
Opp 6
Risk 3

Thesis: Risk remains moderate because the reviewed sources provide only supporting article context with neutral polarity rather than direct positive or negative events, and some support is company-sourced, so execution, demand conversion, and economic durability are not independently validated here

Why now: The recency stack is favorable for a 1 year+ thesis: May 1, 2026 launch progress, May 21, 2026 operating-profile context, and June 3, 2026 alliance expansion together suggest that constellation buildout and service-capability scaling were active in the most recent recent evidence window period

Evidence
  • May 1, 2026: article says Rocket Lab successfully launched Synspective's ninth StriX SAR satellite and that the mission improved the company's ability to deliver persistent Earth observation capabilities. friendsofnasa.org
  • June 3, 2026: Synspective and KSAT expanded their strategic alliance to support expansion of Synspective's SAR constellation and strengthen global Earth observation capabilities. synspective.com
  • May 21, 2026: company page says Synspective designs, builds, and operates a fleet of SAR satellites and provides SAR data sales and solution services to government agencies and companies worldwide. synspective.com

Caveats: Evidence is supporting article context and mostly neutral-polarity in reviewed sources structure, not direct dated event/facts. Two key supportive items are company-sourced pages/press releases. No retained adverse evidence exists, but absence of bad news is not proof of low risk.

111
TakeMe2Space
mediummedium
Opp 7
Risk 3

Thesis: The reviewed sources contain no direct negative evidence; risk is mainly that the evidence is still supporting article context rather than a more detailed direct event/fact trail on disbursement timing, commercial conversion, or technical milestones.

Why now: The IN-SPACe funding article is dated June 12, 2026, very recent within the recent evidence window, and describes first investment into selected Indian spacetech startups including TakeMe2Space, which could shape the next year of development. Source date: June 12, 2026

Evidence
  • IN-SPACe selected TakeMe2Space under its Technology Adoption Fund scheme; the article states the selected startups will each receive a maximum of ₹25 crore to support their projects. June 12, 2026. startup.economictimes.indiatimes.com

Caveats: Reviewed evidence notes prior broader membership support, but only one in-window article context is retained here. Evidence is supporting article context only despite stronger historical support counts.

112
Telesat Corporation
lowweak
Opp 2
Risk 3

Thesis: Risk stems from lack of current supporting evidence around rollout progress in these reviewed sources rather than any direct adverse event.

Why now: No within the recent evidence window evidence were available for Telesat Corporation, so there is no current evidence-set-backed catalyst despite the membership rationale referencing future constellation timing.

Caveats: Membership rationale references article IDs and, but their contents are not included here for direct citation. Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. As a result, scores are necessarily conservative.

113
ThinkOrbital
lowweak
Opp 4
Risk 3

Thesis: Risk is moderate because the reviewed sources provide only article-level company website context, with no direct contracts, funding, launches, or customer wins in the retained evidence. Product ambition is clearer than commercial proof.

Why now: Why now is the dated company-context article from May 28, 2026, recent within the recent evidence window, but it is still weak grounding because it is article-level website context rather than a confirmed business event.

Evidence
  • Company-context article says ThinkX is 'the missing piece of space domain awareness' and ThinkToolkit is a robotic arm/end effector for in-space servicing, construction, inspection and military ops. Article timestamp May 28, 2026. thinkorbital.com

Caveats: Evidence is article-level website context, not direct contract or financing evidence. Single-source evidence limits corroboration. No dated proof of revenue, customer adoption, or deployment is included.

114
Turion Space
lowweak
Opp 3
Risk 3

Thesis: No direct negative evidence is included; risk is mostly uncertainty from missing current corroboration rather than adverse developments.

Why now: No within the recent evidence window evidence was available in these reviewed sources, so the timing case is weak despite the strategic framing in the membership rationale.

Caveats: Membership rationale references article IDs and, but no article content is provided here for citation. Evidence recent evidence review shows 0 kept rows. Scores remain conservative because the reviewed sources lack usable direct evidence.

115
Ulook
lowweak
Opp 2
Risk 3

Thesis: Primary risk is execution and evidence opacity rather than a documented adverse event. The reviewed sources contain no direct negative evidence, but also no available positive event/fact evidence after recent evidence window, leaving material uncertainty around financing, milestones, and traction.

Why now: Why now is weak because the reviewed sources show two articles were considered for membership support, yet zero article context or evidence were available after recent evidence window; recency and milestone timing are therefore uncertain. The membership rationale references article IDs and, but no or article dates were provided in the reviewed sources.

Caveats: No direct positive or negative evidence were provided after recent evidence window. Membership rationale references article IDs and, but no are available, so those claims cannot be fully cited under the the evidence standard. Opportunity score is kept low because membership is not thesis attractiveness.

116
UNASTELLA Corporation
mediummedium
Opp 6
Risk 3

Thesis: No direct adverse evidence is provided, but as a rocket startup the reviewed sources only gives article-level funding context without additional confirmation on milestones, contracts, or operating traction, leaving execution risk high relative to evidence depth.

Why now: The funding context is dated June 1, 2026 and sits well within the 90-day recent evidence window, making it recent enough to support a 1 year+ development runway thesis. Source date: June 1, 2026

Evidence
  • The article says Seoul-based rocket startup UNASTELLA Corporation raised $24 million to develop its own launch vehicles and engines and is expanding its capabilities. June 1, 2026. linkedin.com

Caveats: Evidence is from a LinkedIn space briefing and is supporting article context only. No direct product milestone, customer, or contract evidence is available.

117
Vast, Inc.
lowweak
Opp 3
Risk 3

Thesis: Commercial space station development is inherently execution-intensive, but these reviewed sources includes no direct adverse evidence within the recent evidence window.

Why now: Why-now is unproven from these reviewed sources because no dated evidence survived the 90-day recent evidence window despite 11 articles considered.

Caveats: Phase2 membership rationale references and, but no summaries or evidence are available for citation. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scores remain near low baseline due to absence of directly citable local evidence.

118
Voyager Space
mediummedium
Opp 6
Risk 3

Thesis: Risk is moderate rather than low because most of the evidence is supporting article context, not positive evidence, and part of the recent award activity is defense-oriented rather than directly proving commercial space monetization breadth

Why now: The timing is comparatively favorable: Voyager has dated within the recent evidence window evidence published May 26, 2026 for a $16.5M DARPA Phase 2 contract, May 29, 2026 defense/national security capability context, and June 4, 2026 current company capability context, all within the reviewed sources recent evidence window and relevant to a 1 year+ horizon

Evidence
  • Published May 26, 2026: Voyager Technologies was awarded a DARPA Burn n' Go Phase 2 contract valued at $16.5 million to advance propulsion control technology. voyagertechnologies.com
  • Published June 4, 2026: Voyager says its electric propulsion capabilities for satellite constellations and spacecraft are critical and describes broader advanced space technologies. voyagertechnologies.com

Caveats: Much of the evidence is supporting article context rather than direct positive rows. Some cited capability pages are company-provided materials. Ticker is absent in the required company entry even though external articles reference NYSE: VOYG; this output preserves the required ticker field from the input.

119
Voyager Technologies, Inc.
lowweak
Opp 3
Risk 3

Thesis: The absence of fresh evidence is itself the main risk for ranking purposes: there is no available adverse event, but also no post-recent evidence window proof of progress on a capital-intensive program, leaving the name unrankable beyond a low-conviction watchlist stance.

Why now: No current catalyst is evidenced in the reviewed sources. Although membership support references article IDs and, the reviewed sources show 0 article IDs after recent evidence window and 0 evidence after recent evidence window, so business-state recency cannot be established.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources provide no or article summaries for citation.

120
VyomIC
lowweak
Opp 4
Risk 3

Thesis: The same rationale points to long-dated milestones, with first satellites planned for 2027 and 2028, implying material schedule, financing, and execution risk over the forecast horizon. No direct negative event is available, but the business appears early-stage from the reviewed sources.

Why now: Why now is moderate only because the business is framed around future constellation deployment and milestone timing beyond the immediate term; however, recency cannot be validated because no recent evidence window evidence are available.

Caveats: Membership rationale cites article IDs and, but no are present. No representative article text or direct event/facts are available after the 90-day recent evidence window. Scoring reflects early-stage optionality and execution risk, not direct verified traction.